SAFETY DATA SHEETS

This SDS packet was issued with item: 078937198

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078928778 078936858 078937224 078938015 078944764 078944769 078944797 078945422 078945455 078945456 078945457 078950117 078950401



SECTION 1: IDENTIFICATION

| 1.1 Product identifier | | | | |
|---|--|--|--|--|
| Product name | e Clavacillin® (amoxicillin and clavulanate potassium tablets), USP Veterinary Tablets | | | |
| Chemical name | Not Applicable | | | |
| Synonyms | Amoxicillin and clavulanate potassium tablets | | | |
| Chemical formula | Not Applicable | | | |
| Other means of identification | Not Available | | | |
| 1.2 Recommended use of the che | mical and restrictions on use | | | |
| | Oral tablet / antibiotic. For professional use only. Not for human use. | | | |
| 1.3 Details of the supplier of the substance or mixture | | | | |
| Registered company name (US) Dechra Veterinary Products | | | | |
| Address | 7015 College Blvd, Suite 525, Overland Park, KS 66211 USA | | | |
| Telephone | 866-933-2472 | | | |
| Fax | Not Available | | | |
| Email | Not Available | | | |
| 1.4 Emergency telephone numbers | | | | |
| Dechra (US) | 866-933-2472 | | | |

SECTION 2: HAZARD(S) IDENTIFICATION

| SECTION 2. THAL | ard(3) Iden Inication | | | | |
|---|--|--|--|--|--|
| 2.1 Classification of the substance or mixture | | | | | |
| NFPA 704 diamon | d | | | | |
| 2 0 | Note: The hazard category numbers found in GHS classification in section 2 of this SDSs are NOT to be used to fill in the NFPA 704 diamond. Blue = Health Red = Fire Yellow = Reactivity White = Special (Oxidizer or water reactive substances) | | | | |
| Classification | Skin Corrosion/Irritation Category 2, Sensitization (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 2A, Sensitization (Respiratory) Category 1, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Carcinogenicity Category 1A, Specific Target Organ Toxicity - Repeated Exposure Category 2 | | | | |
| 2.2 Label elements | | | | | |
| Hazard pictogram(s) | | | | | |
| Signal word | | | | | |
| Hazard statement(s | | | | | |
| | Causes skin irritation. | | | | |
| | May cause an allergic skin reaction. | | | | |
| | Causes serious eye irritation. | | | | |
| | May cause allergy or asthma symptoms or breathing difficulties if inhaled. | | | | |
| | May cause respiratory irritation. | | | | |
| | May cause cancer. | | | | |
| | May cause damage to organs through prolonged or repeated exposure. | | | | |
| Hazard(s) not other Not Applica | | | | | |
| | ement(s) Prevention | | | | |
| P201 | Obtain special instructions before use. | | | | |
| P260 | Do not breathe dust/fume. | | | | |
| | Avoid breathing dust/fumes. | | | | |
| P271 | Jse only outdoors or in a well-ventilated area. | | | | |
| | Wear protective gloves, protective clothing, eye protection and face protection. | | | | |
| | [In case of inadequate ventilation] wear respiratory protection. | | | | |
| P202 | Do not handle until all safety precautions have been read and understood. | | | | |
| P264 | | | | | |
| P272 | Contaminated work clothing must not be allowed out of the workplace. | | | | |
| Precautionary state | ment(s) Response | | | | |
| | IF INHALED: Remove person to fresh air and keep comfortable for breathing. | | | | |
| P308+P313 | IF exposed or concerned: Get medical advice/ attention. | | | | |
| P342+P311 | If experiencing respiratory symptoms: Call a POISON CENTER/doctor/physician/first aider. | | | | |
| P305+P351+P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy | | | | |
| P312 | to do. Continue rinsing. Call a POISON CENTER/doctor/physician/first aider/if you feel unwell. | | | | |
| | Get medical advice/attention if you feel unwell. | | | | |
| | If skin irritation or rash occurs: Get medical advice/attention. | | | | |
| | If eye irritation persists: Get medical advice/attention. | | | | |
| | IF ON SKIN: Wash with plenty of water. | | | | |
| | IF ON SKIN: wash with pienty of water. If skin irritation occurs: Get medical advice/attention. | | | | |
| | | | | | |
| P362+P364 Take off contaminated clothing and wash it before reuse. Precautionary statement(s) storage | | | | | |
| | | | | | |
| P405 | Store locked up. | | | | |



| P403+P233 | Store in a well-ventilated place. Keep container tightly closed. | | |
|-------------------------------------|---|--|--|
| Precautionary statement(s) disposal | | | |
| P501 | Dispose of contents/container to authorised hazardous or special waste collection point in accordance | | |
| | with any local regulation. | | |

SECTION 3: COMPOSITION / INFORMATION ON INGREDIENTS

3.1 Substances

See section below for composition of Mixtures.

| 3.2 Mixtures | | | | |
|--|------------|-------------------------------|--|--|
| CAS No. | % [weight] | Name | | |
| 61336-70-7 | 30-60 | amoxycillin trihydrate | | |
| 9004-34-6 | 30-60 | microcrystalline cellulose | | |
| 61177-45-5 | 10-30 | potassium clavulanate | | |
| 9063-38-1 | 1-10 | sodium starch glycolate | | |
| 557-04-0 | 1-10 | magnesium stearate | | |
| 9004-65-3 | <1 | hydroxypropyl methylcellulose | | |
| 7631-86-9 | <1 | colloidal silicon dioxide | | |
| 13463-67-7 | <1 | titanium dioxide | | |
| 25322-68-3 | <1 | polyethylene glycol 6000 | | |
| 14807-96-6 | <1 | talc_ | | |
| 51274-00-1 | <1 | iron oxide yellow | | |
| The exact percentage (concentration) of composition has been withheld as a trade secret. | | | | |
| SECTION 4: FIRST AID MEASURES | | | | |

| 4.1 Description | n of first aid measures | | | |
|--|--|--|--|--|
| Eye contact | If this product comes in contact with the eyes: wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. | | | |
| | Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. | | | |
| Skin contact | If skin contact occurs: immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation. | | | |
| Inhalation | If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor, without delay. | | | |
| Ingestion If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice. | | | | |
| 4.2 Most important symptoms and effects, both acute and delayed See section 11. | | | | |
| 4.3 Indication | 4.3 Indication of immediate medical attention and special treatment needed | | | |

Treat symptomatically.

SECTION 5: FIRE FIGHTING MEASURES

5.1 Extinguishing media

There is no restriction on the type of extinguisher which may be used. Use extinguishing media appropriate for surrounding fire.

5.2 Special hazards arising from the substance or mixture Fire incompatibility Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result. 5.3 Special protective actions for fire-fighters: Firefighting Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use firefighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. Fire / explosion Solid which exhibits difficult combustion or is difficult to ignite. Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any hazard source of ignition, i.e. flame or spark, will cause fire or explosion. Explosion may emit poisonous/corrosive fumes. When heated to extreme temperatures, (>1700°C) amorphous silica can fuse.

SECTION 6: ACCIDENTAL RELEASE MEASURES

| 6.1 | Personal precautions, protective equipment and emergency procedures |
|-----|---|
| | See section 8. |
| 6.2 | Environmental precautions |
| | See Section 12 |



| 6.3 Methods and mate | erial for containment and cleaning up |
|-----------------------|--|
| Minor spills | Clean up waste regularly and abnormal spills immediately. Avoid breathing dust and contact with skin |
| - | and eyes. Wear protective clothing, gloves, safety glasses and dust respirator. Use dry clean up |
| | procedures and avoid generating dust. Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted |
| | with an exhaust micro filter (H-Class HEPA type) (consider explosion-proof machines designed to be |
| | grounded during storage and use). H-Class HEPA filtered industrial vacuum cleaners should NOT be |
| | used on wet materials or surfaces. Dampen with water to prevent dusting before sweeping. Place in |
| | |
| | suitable containers for disposal. |
| Major spills | Moderate hazard. |
| | CAUTION: Advise personnel in area. Alert Emergency Services and tell them location and nature of |
| | hazard. Control personal contact by wearing protective clothing. Prevent, by any means available, |
| | spillage from entering drains or water courses. Recover product wherever possible. |
| | IF DRY: Use dry clean up procedures and avoid generating dust. Collect residues and place in sealed |
| | |
| | plastic bags or other containers for disposal. IF WET: Vacuum/shovel up and place in labelled containers |
| | for disposal. ALWAYS: Wash area down with large amounts of water and prevent runoff into drains. |
| | If contamination of drains or waterways occurs, advise Emergency Services. |
| Personal Protective F | auinment advice is contained in Section 8 of the SDS |

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7: HANDLING AND STORAGE

| 7.1 Precautions for | |
|----------------------------|---|
| Safe handling | Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. DO NOT allow material to contact humans, exposed food or food utensils. Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. Work clothes should be laundered separately. Launder contaminated clothing before re-use. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. |
| Other information | Store in original containers. Keep containers securely sealed. Store in a cool, dry area protected from environmental extremes. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. For major quantities: Consider storage in bunded areas - ensure storage areas are isolated from sources of community water (including stormwater, ground water, lakes and streams). Ensure that accidental discharge to air or water is the subject of a contingency disaster management plan; this may require consultation with local authorities. |
| 7.2 Conditions for | safe storage, including any incompatibilities |
| Suitable container | Tablets are packaged in foil strip packs. Glass container is suitable for laboratory quantities Polyethylene or polypropylene container. Check all containers are clearly labelled and free from leaks. |
| Storage incompatibility | Protect from direct sunlight. Do not freeze. Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F). Avoid strong acids, bases and oxidizing agents. |

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

| 8.1 Control parameters | 8.1 Control parameters | | | | | |
|---|-------------------------------|---|------------------------------------|------------------|------------------|------------------|
| Occupational Exposure Limits (OEL) | | | | | | |
| INGREDIENT DATA | | | | | | |
| Source | Ingredient | Material name | TWA | STEL | Peak | Notes |
| US OSHA Permissible Exposure Limits (PELs)Table Z-3 | | Inert or Nuisance Dust: Respirable fraction | 5 mg/m ³ / 15 mppcf | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-3 | | Inert or Nuisance Dust: Total Dust | 15 mg/m ³ / 50 mppcf | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-1 | | Cellulose- Total dust | 15 mg/m ³ | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-1 | microcrystalline cellulose | Cellulose- Respirable fraction | 5 mg/m ³ | Not Available | Not Available | Not Available |
| US NIOSH Recommended Exposure Limits (RELs) | | Cellulose - total | 10 mg/m ³ | Not Available | Not Available | Not Available |
| US NIOSH RELS | | Cellulose - respirable | 5 mg/m ³ | Not Available | Not Available | Not Available |
| US ACGIH Threshold Limit Values (TLV) | | Cellulose | 10 mg/m ³ | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-3 | | Inert or Nuisance Dust: Respirable fraction | 5 mg/m ³ / 15 mppcf | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-3 | magnesium | Inert or Nuisance Dust: Total Dust | 15 mg/m ³ / 50 mppcf | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-1 | stearate | Particulates Not Otherwise Regulated(PNOR)- Total dust | 15 mg/m ³ | Not Available | Not Available | Not Available |
| US OSHA PELs Table Z-1 | | PNOR - Respirable fraction | 5 mg/m ³ | Not Available | Not Available | Not Available |



| | [| 1 | | | 1 | | |
|---|--|---|---|--|--------------------------------|--|--------------------------|
| US NIOSH (RELs | | PNOR | | Not Available | Not Availab | Not le Available | See Appendix D |
| US ACGIH TLV | | Stearates (Inhalable particulate matter) | | 10 mg/m ³ | Not Availab | | A4 |
| US ACGIH TLV | | Stearates (Respira particulatematter) | able | 3 mg/m ³ | Not Availab | Not le Available | A4 |
| US OSHA PELs Table Z-3 | | Amorphous, includ diatomaceous ea | | 80 (%SiO ₂) mg/m ³ / 20 mppcf | Availab | | Not Available |
| US OSHA PELs Table Z-1 | colloidal silicon dioxide | PNOR - Respirab | le fraction | 5 mg/m ³ | Not Availab | Not le Available | Not Available |
| US OSHA PELs Table Z-1 | uloxide | PNOR - Total dus | st | 15 mg/m³ | Not Availab | Not le Available | Not Available |
| US NIOSH RELS | | Silica, amorphous | | 6 mg/m ³ | Not Availab | Not le Available | Not Available |
| US OSHA PELs Table Z-3 | | Inert or Nuisance Dust | | 15 mg/m ³ / 50 mppcf | Not Availab | | Not Available |
| US OSHA PELs Table Z-3 | | Inert or Nuisance Respirable fraction | | 5 mg/m ³ / 15 mppcf | Not Availab | Not le Available | Not Available |
| US OSHA Permissible Exposure Limits (PELs)Table Z-1 | titanium dioxide | • | | 15 mg/m ³ | Not Availab | Not | Not Available |
| US NIOSH RELS | | Titanium dioxide | | Not Available | Not Availab | Not le Available | Ca; See Appendix A |
| US ACGIH TLV | | Titanium dioxide | | 10 mg/m ³ | Not Availab | Not | (A4) |
| US OSHA PELs Table Z-3 | | Silicates (less that crystallinesilica): | Soapstone | 20 mppcf | Not Availab | Not | Not Available |
| US OSHA PELs Table Z-3 | | Silicates (less than 1% crystallinesilica): Talc (containing asbestos) | | Not Available | Not Availab | Not Available | Use asbestos limit |
| US OSHA PELs Table Z-3 | | Silicates (less than 1% crystalline silica): Talc (not containing asbestos) | | 20 mppcf | Not Availab | Not Available | Not Available |
| US OSHA PELs Table Z-1 | tolo | PNOR - Respirable fraction | | 5 mg/m ³ | Not Availab | Not le Available | Not Available |
| US OSHA PELs Table Z-1 | talc | PNOR - Total dust | | 15 mg/m ³ | Not Availab | Not | Not Available |
| US NIOSH RELS | | Talc (containing no asbestos and lessthan 1% quartz) - respirable | | 2 mg/m ³ | Not Availab | Not Available | Not Available |
| US ACGIH Threshold Limit Values (TLV) | | Talc: Containing asbestos fibers | | Not Available | Not Availab | Not le Available | A1 |
| US ACGIH TLV | | Talc: Containing no asbestos fibers(Respirable particulate matter) | | 2 mg/m3 | Not Availab | Not Available | A4 |
| US OSHA PELs Table Z-3 | | | | 5 mg/m ³ / 15 mppcf | Not Availab | Not le Available | Not Available |
| US OSHA PELs Table Z-3 | | Inert or Nuisance Dust: Total Dust | | 15 mg/m ³ / 50 mppcf | Not Availab | Not le Available | Not Available |
| US OSHA PELs Table Z-1 | iron oxide yello | W PNOR - Total dus | PNOR - Total dust | | Not Availab | Not le Available | Not Available |
| US OSHA PELs Table Z-1 | | PNOR - Respirable fraction | | 5 mg/m ³ | Not Availab | Not le Available | Not Available |
| US NIOSH RELS | | PNOR | PNOR | | Not Availab | Not Available | See Appendix D |
| Emergency Limits | | | | | | | |
| Ingredient | TEEL-1 | | TEEL-2 | | | TEEL-3 | |
| | 18 mg/m ³ 18 mg/m ³ | | 200 mg/m ³ 100 mg/m ³ 1,300 mg/m ³ | | | 1,200 mg/m ³ 630 mg/m ³ | |
| colloidal silicon dioxide | 120 mg/m ³ | | | | 7,900 mg/m ³ | | |
| | 45 mg/m ³ | | 500 mg/m ³ | | 3,000 mg/m ³ | | |
| | 18 mg/m ³ | | 740 mg/m ³ | | | 4,500 mg/m ³ | |
| titanium dioxide | 30 mg/m ³ | 330 mg/m ³ | | | | 2,000 mg/m ³ | |
| polyethylene glycol 6000 | 30 mg/m ³ | | 1,300 mg/m ³ | | | 7,700 mg/m ³ | |
| Ingredient | | | Driginal IDLH | | ed IDLH | | |
| | | | Not Available | | vailable | | |
| | | Not Available | | | Not Available | | |
| | | Not Available | Not Available | | Not Available Not Available | | |
| magnesium stearate | | Not Available | | | Not Available | | |
| hypromellose E5 | | | | | | | |
| | | | | Not Available | | | |



| aallaidal ailiaan diavida | | $2.000 m a/m^2$ | Not Available |
|---|--|--------------------------------------|---|
| | | 3,000 mg/m3 | Not Available |
| | | 5,000 mg/m3 | Not Available |
| polyethylene glycol 6000 | | Not Available | Not Available |
| talc | | 1,000 mg/m ³ | Not Available |
| iron oxide yellow | | Not Available | Not Available |
| Occupational Exposure Bane | ding | | |
| Ingredient | | Occupational Exposure Band Rating | Occupational Exposure Band Limit |
| amoxicillin trihydrate | | E | ≤ 0.01 mg/m³ |
| potassium clavulanate | | E | ≤ 0.01 mg/m ³ |
| chemical's potency and the occupational exposureband (worker health | adverse heal | th outcomes associated with exposu | cific categories or bands based on a ure. The output of this process is an incentrations that are expected to protect |
| 8.2 Exposure controls | n | | |
| Appropriate engineering controls | Emergency | | e ventilation, especially in confined areas. ers should be available in the immediate l/local regulations are observed. |
| Personal protection | | | |
| Eye and face protection | When handling very small quantities of the material eye protection may not be required. For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs wear chemical goggles with side-shields. Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, | | |
| Skin and body protection | Wear suitable protective clothing if skin contact with drug product is possible. See Hand protection above. | | |
| Hand/feet protection | The material may produce skin sensitization in predisposed individuals. Care must be taken, when removing gloves and otherprotective equipment, to avoid all possible skin contact. Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed. Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent). | | |
| Other protection | For up to 500 g a laboratory coat may be suitable. For up to 1 kg a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs. For over 1 kg and manufacturing operations, wear disposable coverall of low permeability and disposableshoe covers. Eye wash unit and ready access to an emergency shower. For Emergencies: Vinyl suit | | |
| Respiratory protection | Type -P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent). If exposure limits are exceeded or irritation is experienced, ventilation and excavation may be required. | | |

| SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES | | | | |
|---|--|--|--|--|
| 9.1 Information on basic physical and chemical propertie | es | | | |
| Appearance: Yellowish tablets | Vapor density: Not Available | | | |
| Physical state: Solid | Auto ignition temperature (°C): Not Available | | | |
| Odor: Not Available | Decomposition temperature (°C): Not Available | | | |
| Odor threshold: Not Available | Viscosity (°C): Not Available | | | |
| pH (as supplied): Not Available | Explosive properties: Not Available | | | |
| Melting point / freezing point (°C): Not Available | Oxidizing properties: Not Available | | | |
| Initial boiling point and boiling range: Not Available | Partition coefficient: Not Available | | | |
| Flash point (°C): Not Available | Molecular weight: Not Available | | | |
| Evaporation rate: Not Available | Taste: Not Available | | | |
| Flammability: Not Available | Surface tension: Not Available | | | |
| Upper/lower flammability or explosive limits: Not Available | Volatile component (%vol): Not Available | | | |
| Vapor pressure: Not Available | Gas group: Not Available | | | |
| Relative density (Water = 1): Not Available | pH as a solution: Not Available | | | |
| Solubility in water (mg/l): Immiscible | VOC g/L: Not Available | | | |
| | Specific gravity @ 20°C (water = 1): Not Available | | | |

| SECTION 10: STABILITY AND REACTIVITY | | | |
|--------------------------------------|---|--|--|
| Reactivity | See Section 7 | | |
| Chemical stability | Unstable in the presence of incompatible materials. Product is considered stable. | | |
| | Hazardous polymerization will not occur. | | |
| Possibility of hazardous reactions | See Section 7 | | |
| Conditions to avoid | See Section 7 | | |
| Incompatible materials | See Section 7 | | |
| Hazardous composition | See Section 5 | | |



| Ingestion // Skin contact // Skin contact // Eye // Eye // Chronic // Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets // amoxycillin trihydrate // microcrystalline cellulose // potassium clavulanate // potassium stearate // magnesium stearate // hypromellose E5 // colloidal silicon dioxide // | Inhalation of vapors c normal handling, may Accidental ingestion of The liquid may be mis described as non-all dermatitis as describ exposed to this mate puncture wounds or le Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dard(rat) $LD_{50} > 2000$ Toxicity Oral(mouse) $LD_{50} : 45$ Toxicity | y be damaging to t of the material ma scible with fats or of lergic contact derived regic contact derived regi | fumes), generated by the material during the course health of the individual. / be damaging to individual's health. Is and may degrease the skin, producing a skin reanatitis. The material is unlikely to produce an in es Open cuts, abraded or irritated skin should ne blood-stream through, for example, cuts, abrase systemic injury with harmful effects. Interce predicts, that the material either produal number of individuals following direct contact, a napplied to the healthy intact skin of animals. e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Irritation Irritation Irritation Irritation | | |
|--|--|---|---|--|--|
| Inhaled Ingestion Skin contact Skin contact Eye Chronic Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 | Inhalation of vapors c normal handling, may Accidental ingestion of The liquid may be mis described as non-all dermatitis as describ exposed to this mate puncture wounds or le Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dermal(rabbi) $LD_{50} > 2000$ Toxicity Dard(rat) $LD_{50} > 2000$ Toxicity Oral(mouse) $LD_{50} : 45$ Toxicity | y be damaging to t of the material ma scible with fats or of lergic contact derived regic contact derived regi | he health of the individual. v be damaging to individual's health. Is and may degrease the skin, producing a skin reanatitis. The material is unlikely to produce an ineso Open cuts, abraded or irritated skin should neblood-stream through, for example, cuts, abrase systemic injury with harmful effects. ience predicts, that the material either prod al number of individuals following direct contact, a napplied to the healthy intact skin of animals. e predicts, that the material may cause eye irritat/or may produce significant ocular lesions. Irritation Not Available Irritation Not Available | | |
| Ingestion / Skin contact / Skin contact / Eye / Eye / Chronic / Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets / amoxycillin trihydrate / microcrystalline cellulose / potassium clavulanate / potassium stearate / magnesium stearate / hypromellose E5 / colloidal silicon dioxide / | Accidental ingestion of The liquid may be mis described as non-all- dermatitis as describ exposed to this mate puncture wounds or le Evidence exists, or inflammation of the s produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Toxicity Dermal(rabbit) LD ₅₀ >200 Toxicity Dermal(rabbit) LD ₅₀ >2000 Toxicity Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | of the material ma scible with fats or of lergic contact derived in EC Directived erial. Entry into the esions, may produce r practical experience ractical experience of individuals and 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | v be damaging to individual's health. Is and may degrease the skin, producing a skin reanatitis. The material is unlikely to produce an ineso Open cuts, abraded or irritated skin should neso bood-stream through, for example, cuts, abrase experime injury with harmful effects. ience predicts, that the material either prod al number of individuals following direct contact, a napplied to the healthy intact skin of animals. e predicts, that the material may cause eye irritate /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Skin contact Skin | The liquid may be mis described as non-all dermatitis as describ exposed to this mate puncture wounds or le Evidence exists, or n a substantial number Toxicity Not Available Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dral(mouse) $LD_{50} : 45$ Toxicity | scible with fats or clergic contact derived in EC Directiverial. Entry into the esions, may produin r practical experiences in a substanti inflammation whee tractical experiences of individuals and provide the state of the sta | Is and may degrease the skin, producing a skin rea natitis. The material is unlikely to produce an in es Open cuts, abraded or irritated skin should n e blood-stream through, for example, cuts, abras be systemic injury with harmful effects. The predicts, that the material either prod al number of individuals following direct contact, a n applied to the healthy intact skin of animals. The predicts, that the material may cause eye irritat for may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Eye Chronic Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | described as non-all dermatitis as describ exposed to this mate puncture wounds or le Evidence exists, or inflammation of the s produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rabit) $LD_{50} > 2000$ Toxicity Dermal(rabit) $LD_{50} > 2000$ Toxicity Dral(rat) $LD_{50} > 5000$ Toxicity Oral(mouse) $LD_{50} : 45$ Toxicity | lergic contact derived in EC Directiverial. Entry into the esions, may produir practical experies skin in a substanti inflammation whe inactical experience of individuals and product the state of the | natitis. The material is unlikely to produce an in es Open cuts, abraded or irritated skin should n e blood-stream through, for example, cuts, abrass ce systemic injury with harmful effects. ence predicts, that the material either prod al number of individuals following direct contact, a n applied to the healthy intact skin of animals. e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Eye Eye Chronic Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | dermatitis as describ exposed to this mate puncture wounds or le Evidence exists, or inflammation of the s produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rabit) $LD_{50} > 2000$ Toxicity Dard(rat) $LD_{50} > 5000$ Toxicity Oral(rat) $LD_{50} > 5000$ Toxicity Oral(mouse) $LD_{50}: 45$ Toxicity | bed in EC Directiverial. Entry into the esions, may produce the sions, may produce the sion | es Open cuts, abraded or irritated skin should n e blood-stream through, for example, cuts, abrass ce systemic injury with harmful effects. ience predicts, that the material either prod al number of individuals following direct contact, a <u>n applied to the healthy intact skin of animals</u> . e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Eye Eye Chronic Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | exposed to this mate puncture wounds or le Evidence exists, or inflammation of the s produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) $LD_{50} > 200$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Dermal(rat) $LD_{50} > 2000$ Toxicity Oral(rat) $LD_{50} > 5000$ Toxicity Oral(mouse) $LD_{50}: 45$ Toxicity | erial. Entry into th esions, may produ r practical experi- skin in a substanti inflammation whe ractical experience r of individuals and 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | e blood-stream through, for example, cuts, abrass ce systemic injury with harmful effects. ience predicts, that the material either prod al number of individuals following direct contact, a <u>n applied to the healthy intact skin of animals</u> . e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Eye Eye Chronic Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | puncture wounds or le Evidence exists, or inflammation of the s produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Toxicity Dermal(rabit) LD ₅₀ > Inhalation(rat) LC ₅₀ > Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | esions, may produ r practical experi- skin in a substanti inflammation whe ractical experience r of individuals and 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | ce systemic injury with harmful effects. ience predicts, that the material either prod al number of individuals following direct contact, a in applied to the healthy intact skin of animals. e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Eye Chronic Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 | Evidence exists, or inflammation of the s produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Oral(rat) LD ₅₀ >2000 Toxicity Dermal(rabbit) LD ₅₀ > Onal(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | r practical exper skin in a substanti inflammation whe ractical experienc r of individuals and 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | ence predicts, that the material either prod al number of individuals following direct contact, a n applied to the healthy intact skin of animals. e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available | | |
| Chronic Chroni | produces significant i Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Toxicity Dermal(rabbit) LD ₅₀ >2000 Toxicity Dermal(rabbit) LD ₅₀ >2000 Toxicity Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | inflammation whe practical experience r of individuals and 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | n applied to the healthy intact skin of animals. e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available Irritation | | |
| Chronic 1 Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets - amoxycillin trihydrate - amoxycillin trihydrate - microcrystalline cellulose - potassium clavulanate - potassium clavulanate - hypromellose E5 - colloidal silicon dioxide - | Evidence exists, or p a substantial number Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Oral(rat) LD ₅₀ >200 Toxicity Dermal(rabbit) LD ₅₀ > Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | of individuals and of individual | e predicts, that the material may cause eye irritat /or may produce significant ocular lesions. Irritation Not Available Irritation Not Available Irritation Not Available Not Available | | |
| Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 | a substantial number Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Oral(rat) LD ₅₀ >2000 Toxicity Dermal(rabbit) LD ₅₀ > Inhalation(rat) LC ₅₀ > Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | r of individuals and 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | /or may produce significant ocular lesions. Irritation Not Available | | |
| Clavacillin (amoxicillin and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 | Toxicity Not Available Toxicity Dermal(rat) LD ₅₀ >200 Oral(rat) LD ₅₀ >2000 Toxicity Dermal(rabbit) LD ₅₀ > Inhalation(rat) LC ₅₀ > Oral(rat) LD ₅₀ >5000 Toxicity Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | 000 mg/kg ^[1] mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Irritation Not Available Irritation Not Available Irritation Not Available Irritation Not Available | | |
| and clavulanate potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 | Not Available Toxicity Dermal(rat) $LD_{50} > 200$ Oral(rat) $LD_{50} > 2000$ Toxicity Dermal(rabbit) $LD_{50} > 2000$ Inhalation(rat) $LC_{50} > 2000$ Oral(rat) $LD_{50} > 5000$ Toxicity Oral(mouse) $LD_{50} : 45$ Toxicity | mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Not Available Irritation Not Available Irritation Not Available | | |
| potassium tablets) USP Veterinary Tablets amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | ToxicityDermal(rat) $LD_{50} > 200$ Oral(rat) $LD_{50} > 2000$ ToxicityDermal(rabbit) $LD_{50} >$ Inhalation(rat) $LC_{50} >$ Oral(rat) $LD_{50} > 5000$ ToxicityOral(mouse) $LD_{50} : 45$ ToxicityToxicity | mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Irritation Not Available Irritation Not Available | | |
| Veterinary Tablets amoxycillin trihydrate imicrocrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | ToxicityDermal(rat) $LD_{50} > 200$ Oral(rat) $LD_{50} > 2000$ ToxicityDermal(rabbit) $LD_{50} >$ Inhalation(rat) $LC_{50} >$ Oral(rat) $LD_{50} > 5000$ ToxicityOral(mouse) $LD_{50} : 45$ ToxicityToxicity | mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Irritation Not Available Irritation Not Available | | |
| amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 | $\begin{array}{l} \mbox{Dermal(rat)} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$ | mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Not Available Irritation Not Available | | |
| amoxycillin trihydrate microcrystalline cellulose potassium clavulanate magnesium stearate hypromellose E5 colloidal silicon dioxide | $\begin{array}{l} \mbox{Dermal(rat)} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$ | mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Not Available Irritation Not Available | | |
| microcrystalline cellulose | $\begin{array}{l} Oral(rat) \ LD_{50} > 2000 \\ \hline \textbf{Toxicity} \\ Dermal(rabbit) \ LD_{50} > \\ Inhalation(rat) \ LC_{50} > \\ Oral(rat) \ LD_{50} > 5000 \\ \hline \textbf{Toxicity} \\ \hline Oral(mouse) \ LD_{50} : 45 \\ \hline \textbf{Toxicity} \end{array}$ | mg/kg ^[1] >2000 mg/kg ^[2] >5.8 mg/L4h ^[2] mg/kg ^[2] | Irritation Not Available | | |
| microcrystalline cellulose | Toxicity Dermal(rabbit) $LD_{50} >$ Inhalation(rat) $LC_{50} >$ Oral(rat) $LD_{50} >$ Toxicity Oral(mouse) LD_{50} : 45 Toxicity | >2000 mg/kg ^[2] •5.8 mg/L4h ^[2] mg/kg ^[2] | Irritation Not Available | | |
| microcrystalline cellulose | Dermal(rabbit) $LD_{50} >$ Inhalation(rat) $LC_{50} >$ Oral(rat) $LD_{50} >$ 5000 Toxicity Oral(mouse) $LD_{50}: 45$ Toxicity | >5.8 mg/L4h ^[2] mg/kg ^[2] | Not Available | | |
| potassium clavulanate magnesium stearate hypromellose E5 | Inhalation(rat) $LC_{50} >$ Oral(rat) $LD_{50} >$ 5000 Toxicity Oral(mouse) LD_{50} : 45 Toxicity | >5.8 mg/L4h ^[2] mg/kg ^[2] | | | |
| potassium clavulanate magnesium stearate hypromellose E5 | Oral(rat) LD ₅₀ >5000 Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | mg/kg ^[2] | | | |
| potassium clavulanate magnesium stearate hypromellose E5 | Toxicity Oral(mouse) LD ₅₀ : 45 Toxicity | | Irritation | | |
| hypromellose E5 | Oral(mouse) LD ₅₀ : 45 Toxicity | 526 mg/kg ^[2] | Irritation | | |
| magnesium stearate hypromellose E5 colloidal silicon dioxide | Toxicity | 526 mg/kg ^{i2j} | | | |
| hypromellose E5 | | | Not Available | | |
| hypromellose E5 | | 0 | Irritation | | |
| colloidal silicon dioxide | Oral(rat) LD ₅₀ >10000 mg/kg ^[2] | | Not Available | | |
| colloidal silicon dioxide | Toxicity Oral(rat) LD ₅₀ >1000 | 0 | Not Available | | |
| colloidal silicon dioxide | | | | | |
| conoidal sincon dioxide | Toxicity | | | | |
| | Dermal(rat) LD50 >20 | | Eye(rabbit): non-irritating* Eye: no adverse effect observed (not irritating) ^[1] | | |
| | Inhalation(rat) LC ₅₀ >0.139 mg/L4h ^[1] | | Skin(rabbit): non-irritating* | | |
| | Oral(rat) LD ₅₀ >1000 mg/kg ^[1] | | Skin: no adverse effect observed (not irritatir | | |
| | Toxicity | | Irritation | | |
| | |) _{₅0} >=10000 ma/ka | Eye: no adverse effect observed (not irritating) ^[1] | | |
| titanium dioxide | Dermal (hamster) $LD_{50} >= 10000 \text{ mg/kg}^{[2]}$ Inhalation(rat) $LC_{50} > 2.28 \text{ mg/l4h}^{[1]}$ | | Skin(human): 0.3 mg /3D (int)-mild* | | |
| | $Oral(rat) LD_{50} >= 2000 mg/kg^{[1]}$ | | Skin: no adverse effect observed (not irritating) ^[1] | | |
| | Toxicity | | Irritation | | |
| F | | | Eye(rabbit): 500 mg/24h –mild | | |
| polyethylene glycol 6000 | Dermal (rat) LD₅₀ >2000 mg/kg ^[1] Oral(rat) LD₅₀; 600 mg/kg ^[2] | | Eye: no adverse effect observed (not irritating) ^[1] | | |
| | | | Skin(rabbit): 500mg (open) mild. | | |
| | | | Skin: no adverse effect observed (not irritating)[1] | | |
| | Toxicity | | Irritation | | |
| talc | Dermal (rat) LD50 >20 | 000 mg/kg ^[1] | Eye: no adverse effect observed (not irritatin | | |
| laic | Inhalation(rat) LC50; | >2.1 mg/l4h ^[1] | Skin(human): 0.3 mg/3d-l mild | | |
| | Oral(rat) LD ₅₀ >5000 mg/kg ^[1] | | Skin: no adverse effect observed (not irritating) ^[1] | | |
| | Toxicity | | Irritation | | |
| iron oxide yellow | Oral(rat) LD50 >5000 | ma/ka ^[2] | Not Available | | |
| 1. Value obtained from Europe | ECHA Registered S | Substances - Acute | toxicity 2.* Value obtained from manufacturer's SDS. | | |
| | | | Toxic Effect of chemical Substances. | | |
| • • • • • | Acute Toxicity | * | Carcinogenicity 🗸 | | |
| Skin Ir | ritation/Corrosion | ✓ | Reproductivity * | | |
| | eDamage/Irritation | ✓ | STOT - Single Exposure 🗸 | | |
| | | | | | |
| | | \checkmark | SIOI - Repeated Exposure V | | |
| > - Data either not available | Skin sensitization Mutagenicity | ✓ ¥ | STOT - Repeated Exposure Aspiration Hazard * | | |

✓ - Data available to make classification

SECTION 12: ECOLOGICAL INFORMATION

| 12.1 Toxicity: No addition | nal information a | available | | | |
|--|-------------------|--------------------|-------------------------------|---------------|---------------|
| Clavacillin (amoxicillin | Endpoint | Test Duration (hr) | Species | Value | Source |
| and clavulanate potassium tablets), USP Veterinary Tablets | Not Available | Not Available | Not Available | Not Available | Not Available |
| | Endpoint | Test Duration (hr) | Species | Value | Source |
| amoxycillin trihydrate | EC50 | 96h | Algae or other aquatic plants | 0.002mg/l | 2 |
| - | EC50 | 72h | Algae or other aquatic plants | 56.3mg/l | 2 |



| | 1.050 | 0.01- | E | | 5 400 m m // | |
|--|-----------------|---|---------------------------|-------------|---------------|----------------|
| | LC50 | 96h | Fish | | >100mg/l | 2 |
| | EC50 | 48h | Crustacea | | >1000mg/l | 2 |
| | NOEC(ECx) | 96h | Algae or other aquati | c plants | 0.001mg/l | 2 |
| microcrystalline cellulose | Endpoint | Test Duration (hr) | Species | | Value | Source |
| | Not Available | | Not Available | | Not Available | Not Available |
| potassium clavulanate | Endpoint | Test Duration (hr) | Species | | Value | Source |
| potassium clavulanate | Not Available | Not Available | Not Available | | Not Available | Not Available |
| adjum starsh shuselsta | Endpoint | Test Duration (hr) | Species | | Value | Source |
| sodium starch glycolate | Not Available | Not Available | Not Available | | Not Available | Not Available |
| | Endpoint | Test Duration (hr) | Species | | Value | Source |
| magnesium stearate | Not Available | Not Available | Not Available | | Not Available | Not Available |
| | Endpoint | Test Duration (hr) | Species | | Value | Source |
| hypromellose E5 | Not Available | | Not Available | | Not Available | Not Available |
| _ | Endpoint | Test Duration (hr) | Species | | Value | Source |
| | EC0(ECx) | 24h | Crustacea | | >=10000mg/l | 1 |
| | EC50 | 72h | Algae or other aguati | ic plante | 14.1mg/l | 2 |
| colloidal silicon dioxide | LC50 | 96h | U U | c plants | 1033.016mg/l | 2 |
| | | | Fish | | | |
| | EC50 | 48h | Crustacea | | >86mg/l | 2 |
| | EC50 | 96h | Algae or other aquati | c plants | 217.576mg/l | 2 |
| | Endpoint | Test Duration (hr) | Species | | Value | Source |
| | EC50 | 72h | Algae or other aquati | c plants | 3.75-7.58mg/l | 4 |
| | BCF | 1008h | Fish | | <1.1-9.6 | 7 |
| titanium dioxide | EC50 | 48h | Crustacea | | 1.9mg/l | 2 |
| | LC50 | 96h | Fish | | 1.85-3.06mg/l | 4 |
| | NOEC(ECx) | 504h | Crustacea | | 0.02mg/l | 4 |
| | EC50 | 96h | Algae or other aguati | ic plants | 179.05mg/l | 2 |
| _ | Endpoint | Test Duration (hr) | Species | - I' | Value | Source |
| | EC50 | 48h | Crustacea | | >100mg/l | 2 |
| polyethylene glycol 6000 | LC50 | 96h | Fish | | >100mg/l | 2 |
| polyetifylerie grycol 0000 | EC50(ECx) | 96h | Algae or other aquati | io plante | >100mg/l | 2 |
| | EC50(ECX) | 96h | U U | | U U | 2 |
| | | | Algae or other aquati | c plants | >100mg/l | |
| | Endpoint | Test Duration (hr) | Species | | Value | Source |
| talc | LC50 | 96h | Fish | | 89581.016mg/l | 2 |
| | NOEC(ECx) | 720h | Algae or other aquati | | 918.089mg/l | 2 |
| | EC50 | 96h | Algae or other aquati | ic plants | 7202.7mg/l | 2 |
| | Endpoint | Test Duration (hr) | Species | | Value | Source |
| iron oxide yellow | NOEC(ECx) | 504h | Fish | | 0.52mg/l | 2 |
| If off oxide yellow | EC50 | 72h | Algae or other aquati | ic plants | 18mg/l | 2 |
| | LC50 | 96h | Fish | | 0.05mg/l | 2 |
| Extracted from 1. IUCLID T | | | | | | |
| Suite V3.12 (QSAR) - Aqua | | | | | | Aquatic Hazard |
| Assessment Data 6. NITE (| | | Japan) - Bioconcentratioi | n Data 8.Ve | endor Data. | |
| DO NOT discharge into | | | | | - | - |
| 12.2 Persistence and de | gradability: No | | | | | |
| Ingredient | | Persistence: Water | /Soil | | ence: Air | |
| amoxycillin trihydrate | | HIGH | | HIGH | | |
| microcrystalline cellulose | | LOW | | LOW | | |
| colloidal silicon dioxide | | LOW | | LOW | | |
| titanium dioxide | | HIGH | | HIGH | | |
| polyethylene glycol 6000 | | LOW | | LOW | | |
| 12.3 Bioaccumulative po | tential: No add | | ailable | | | |
| Ingredient | | Bioaccumulation | | | | |
| amoxycillin trihydrate | | LOW (LogKOW = 0.8 | 7) | | | |
| microcrystalline cellulose | | LOW (LOGKOW = 0.0) LOW (LOGKOW = -5. | | | | |
| | | | | | | |
| colloidal silicon dioxide | | LOW (LogKOW = 0.5) | 294) | | | |
| titanium dioxide | | LOW (BCF = 10) | (000) | | | |
| polyethylene glycol 6000 | | LOW (LogKOW = -1.) | 1996) | | | |
| 12.4 Mobility in soil: No | | | | | | |
| Ingredient | | Mobility | | | | |
| amoxycillin trihydrate | | LOW (KOC = 865.5) | | | | |
| microcrystalline cellulose | | LOW (KOC = 10) | | | | |
| colloidal silicon dioxide | | LOW (KOC = 23.74) | | | | |
| | | | | | | |
| titanium dioxide | | LOW (KOC = 23.74) | | | | |
| titanium dioxide polyethylene glycol 6000 | | LOW (KOC = 23.74) HIGH (KOC = 1) | | | | |

SECTION 13: DISPOSAL CONSIDERATIONS

| 13.1 Waste treatment me | thods |
|-------------------------|---|
| Product/packaging | Containers may still present a chemical hazard/danger when empty. Return to supplier for reuse/ |
| disposal | recycling if possible. Otherwise: If container cannot be cleaned sufficiently well to ensure that |
| _ | residuals do not remain or if the container cannot be used to store the same product, then puncture |
| | containers, to prevent re-use, and bury at an authorised landfill. Where possible retain label warnings |



| and SDS and observe all notices pertaining to the product. DO NOT allow wash water from cleaning or process equipment to enter drains. It may be necessary to collect all wash water for treatment |
|--|
| before disposal. In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. Where in doubt contact the responsible authority. |

SECTION 14: TRANSPORT INFORMATION

Labels required

Marine pollutant NO

Shipping container and transport vehicle placarding and labeling may vary from the below information. Products that are regulated for transport will be packaged and marked as Dangerous Goods in Excepted Quantities according to US DOT, IATA and IMDG regulations. In case of reshipment, it is the responsibility of the shipper to determine the appropriate labels and markings in accordance with applicable transport regulations.

Land transport (DOT): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

| Not Applicable | | |
|---|----------------------------------|--|
| Transport in bulk in accordance with MAR | POL Annex V and the IMSBC Code | |
| Product name | Group | |
| | Not Available for any ingredient | |
| Transport in bulk in accordance with ICG Code | | |
| Product name | Group | |
| | Not Available for any ingredient | |
| | | |

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations / legislation specific for thesubstance or mixture

Product regulated by FDA as a veterinary product.

amoxicillin trihydrate is found on the following regulatory lists Not applicable

microcrystalline cellulose is found on the following regulatory lists

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS). US - Alaska Air Quality Control - Concentrations Triggering an Air Quality Episode for Air Pollutants Other Than PM-2, US -Massachusetts - Right To Know Listed Chemicals, US NIOSH Recommended Exposure Limits (RELs), US OSHA Permissible Exposure Limits (PELs) Table Z-1, US OSHA Permissible Exposure Limits (PELs) Table Z-3, US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

potassium clavulanate is found on the following regulatory lists Not applicable

sodium starch glycolate is found on the following regulatory lists

US TSCA - Chemical Substance Inventory

magnesium stearate is found on the following regulatory lists

International WHO List of Proposed OEL MNMS, US - Alaska Air Quality Control - Concentrations Triggering an Air Quality Episode for Air Pollutants Other Than PM-2, US - Massachusetts - Right To Know Listed Chemicals, US NIOSH RELS, US OSHA PELs Table Z-1, US OSHA PELs Table Z-3, US TSCA - Chemical Substance Inventory

hypromellose E5 is found on the following regulatory lists US TSCA - Chemical Substance Inventory

colloidal silicon dioxide is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List, International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs, MMMS, US - California - Biomonitoring - Priority Chemicals, US - California Proposition 65 - Carcinogens, US - California Safe Drinking Water and Toxic Enforcement Act of 1986 - Proposition 65 List, US - Massachusetts - Right To Know Listed Chemicals, US DOE Temporary Emergency Exposure Limits (TEELs), US NIOSH Carcinogen List, RELs, US OSHA Carcinogens Listing, PELs Table Z-1, PELs Table Z-3, US TSCA - Chemical Substance Inventory, US TSCA Chemical Substance Inventory - Interim List of Active Substances

titanium dioxide is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List, International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs, International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans , MMMS, US - California Proposition 65 - Carcinogens, US -California Safe Drinking Water and Toxic Enforcement Act of 1986 - Proposition 65 List, US - Massachusetts - Right To Know Listed Chemicals, TLV, TLV - Carcinogens, TLV - Notice of Intended Changes, US DOE TEELS, US List of Active Substances Exempt from the TSCA Inventory Notifications (Active-Inactive) Rule, US NIOSH Carcinogen List, RELs, PELs Table Z-1, PELs Table Z-3, US TSCA - Chemical Substance Inventory, US TSCA Chemical Substance Inventory - Interim List of Active Substances

polyethylene glycol 6000 is found on the following regulatory lists

US AIHA Workplace Environmental Exposure Levels (WEELs), TEELs, US TSCA - Chemical Substance Inventory, US Toxicology Excellence for Risk Assessment (TERA) Workplace Environmental Exposure Levels (WEEL), US TSCA



| Chemical Substance Inventory - Interim List of | | | | |
|--|---|---|--|--|
| iron oxide yellow is found on the following reg | | | | |
| | | Control - Concentrations Triggering an Air Quality | | |
| | | To Know Listed Chemicals, US NIOSH RELs, US | | |
| OSHA PELs Table Z-1, US OSHA PELs Table | Z-3, US ISCA - Chemical | Substance Inventory | | |
| Federal Regulations | | | | |
| Superfund Amendments and Reauthorization | on Act of 1986 (SARA) | | | |
| Section 311/312 hazard categories | | | | |
| Flammable (Gases, Aerosols, Liquids, or Solids | 3) | No | | |
| Gas under pressure | | No | | |
| Explosive | | No | | |
| Self-heating | | No | | |
| Pyrophoric (Liquid or Solid) | | No | | |
| Pyrophoric Gas | No | | | |
| Corrosive to metal | No | | | |
| Dxidizer (Liquid, Solid or Gas) | | No | | |
| Organic Peroxide | | No | | |
| Self-reactive | | No | | |
| n contact with water emits flammable gas | | No | | |
| Combustible Dust | | No | | |
| Carcinogenicity | | Yes | | |
| Acute toxicity (any route of exposure) | | No | | |
| Reproductive toxicity | | No | | |
| Skin Corrosion or Irritation | | Yes | | |
| Respiratory or Skin Sensitization | | Yes | | |
| Serious eye damage or eye irritation | | Yes | | |
| Specific target organ toxicity (single or repeated | d exposure) | Yes | | |
| Aspiration Hazard | | No | | |
| Germ cell mutagenicity | | No | | |
| Simple Asphyxiant | | No | | |
| Hazards Not Otherwise Classified | | No | | |
| US. EPA CERCLA Hazardous Substances and | Reportable Quantities (40 | CFR 302.4) | | |
| None Reported | | | | |
| State Regulations | | | | |
| US. California Proposition 65 | | | | |
| A | | | | |
| | | | | |
| | | ng colloidal silicon dioxide, titanium dioxide , | | |
| | | ng colloidal silicon dioxide, titanium dioxide , e information, go to <u>www.P65Warnings.ca.gov</u> . | | |
| which are known to the State of California National Inventory Status | a to cause cancer. For mor | e information, go to <u>www.P65Warnings.ca.gov</u> . | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use | a to causecancer. For mor No (potassium clavulana | e information, go to <u>www.P65Warnings.ca.gov</u> . te) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana | e information, go to <u>www.P65Warnings.ca.gov</u> . te) te) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate | e information, go to <u>www.P65Warnings.ca.gov.</u> te) te) e; potassium clavulanate; sodium starch glycolate; | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h | e information, go to <u>www.P65Warnings.ca.gov.</u> te) te) e; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron ox | e information, go to <u>www.P65Warnings.ca.gov</u> . te) te) e; potassium clavulanate; sodium starch glycolate; hydroxypropyl methylcellulose; polyethylene glycol ide yellow) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate | e information, go to <u>www.P65Warnings.ca.gov</u> . te) te) e; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol | e information, go to <u>www.P65Warnings.ca.gov</u> . te) te) e; potassium clavulanate; sodium starch glycolate; hydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate | e information, go to <u>www.P65Warnings.ca.gov</u> . te) te) e; potassium clavulanate; sodium starch glycolate; hydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS Korea - KECI | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate No (potassium clavulana | e information, go to <u>www.P65Warnings.ca.gov</u> . te) te) e; potassium clavulanate; sodium starch glycolate; hydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS Korea - KECI New Zealand - NZIOC | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate No (potassium clavulana Yes | te information, go to <u>www.P65Warnings.ca.gov</u> . te) te) c; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) te) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS Korea - KECI New Zealand - NZIOC Philippines - PICCS | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate No (potassium clavulana Yes No (potassium clavulana | te information, go to <u>www.P65Warnings.ca.gov</u> . te) te) te) c; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) te) te) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS Korea - KECI New Zealand - NZIOC Philippines - PICCS JSA - TSCA | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate No (potassium clavulana Yes No (amoxycillin trihydrate | te information, go to <u>www.P65Warnings.ca.gov</u> . te) te) te) c; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) te) te) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS Korea - KECI New Zealand - NZIOC Philippines - PICCS JSA - TSCA Taiwan - TCSI | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate No (potassium clavulana No (amoxycillin trihydrate No (amoxycillin trihydrate Yes | te information, go to <u>www.P65Warnings.ca.gov</u> . te) te) te) c; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) te) te) te) | | |
| which are known to the State of California National Inventory Status Australia - AIIC / Australia Non-Industrial Use Canada - DSL Canada - NDSL China - IECSC Europe - EINEC / ELINCS /NLP Japan - ENCS Korea - KECI New Zealand - NZIOC Philippines - PICCS JSA - TSCA Taiwan - TCSI Mexico - INSQ | a to cause cancer. For mor No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (amoxycillin trihydrate No (potassium clavulana No (amoxycillin trihydrate Yes No (potassium clavulana No (amoxycillin trihydrate Yes No (potassium clavulana | te information, go to <u>www.P65Warnings.ca.gov</u> . te) te) te) c; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) te) te) | | |
| | a to cause cancer. For more No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate magnesium stearate; h 6000; talc; C.I. iron oxi No (amoxycillin trihydrate No (sodium starch glycol No (potassium clavulana Yes No (potassium clavulana No (potassium clavulana No (potassium clavulana No (amoxycillin trihydrate No (potassium clavulana No (amoxycillin trihydrate No (potassium clavulana No (potassium clavulana No (potassium clavulana Yes No (potassium clavulana Yes | te information, go to <u>www.P65Warnings.ca.gov</u> . te) te) te) c; potassium clavulanate; sodium starch glycolate; nydroxypropyl methylcellulose; polyethylene glycol ide yellow) e; potassium clavulanate) ate; hydroxypropyl methylcellulose) e; potassium clavulanate) te) te) te) | | |

No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will requireregistration

SECTION 16: OTHER INFORMATION

Initial date: June 2023 – Classification, Product name updated from Clavacillin™ (amoxicillin trihydrate/clavulanate potassium) Veterinary Tablets to Clavacillin® (amoxicillin and clavulanate potassium tablets), USP Veterinary Tablets

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.



Definitions and abbreviations

PC – TWA: Permissible Concentration-Time Weighted Average PC – STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists IDLH: Immediately Dangerous to Life or Health Concentrations AIIC: Australian Inventory of Industrial Chemicals IECSC: Inventory of Existing Chemical Substance in China EINECS: European INventory of Existing Commercial chemical Substances ELINCS: Existing and New Chemical Substances Inventory

ENCS: Existing and New Chemical Substances Inventory PICCS: Philippine Inventory of Chemicals and Chemical Substances INSQ: Inventario Nacional de Sustancias Químicas NCI: National Chemical Inventory

FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

NZIoC: New Zealand Inventory of Chemicals

STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit ES: Exposure Standard OSF: Odor Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odor Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index DSL: Domestic Substances List NDSL: Non-Domestic Substances List NLP: No-Longer Polymers KECI: Korea Existing Chemicals Inventory TSCA: Toxic Substances Control Act TCSI: Taiwan Chemical Substance Inventory

The information provided in this Safety Data Sheet has been compiled by Dechra Veterinary Products LLC and is correct to the best of its knowledge, information and belief as of the date of its publication. However, Dechra Veterinary Products LLC makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness. The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2023 Dechra Veterinary Products LLC. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Veterinary Products LLC products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained Dechra Veterinary Products LLC, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.